StemCell Therapy

Biotechnology simply means to develop or to make useful products with the help of using living systems. Over the years mankind has used biotechnology in several sectors like agriculture, food production and medicine. There are several sectors in which biotechnology can affect severely.

Biotech for human enhancement is the most profitable industry in the 21st century. Careers are influenced by genetic heritage. It is said that by 2020 people will be able to decipher human genome

Which is nothing but the blueprint of our DNA? One of the trends is towards the genetic solutions to the ills. There are several newly discovered drugs will save countless no of lives. These drugs can also eliminate many diseases. A lot of research works have been done on the recent trends for biotechnology. Research output continues to shift to ASIA. The current trends in biotechnology are its association with pharmacy. It is said that within few more years people will be able to turn on or turn off certain genes which can influence on health and performance. People can eliminate unwanted characteristics by using altered genes from their babies. People can also enhance their babies’ capabilities by using the same method. There is different classification of biotechnology having different application of each. Like white or industrial biotechnology helps in the production of chemical base materials and end products. Red biotechnology means development of new medical drugs. Biotechnology is the driving factor behind many applications in medicine. Green or Plant biotechnology is used in production of plants which are renewable recourses. Biotechnology is integrated use of many biological technologies. It also has trends in horticulture. One of the emerging trends in Biotechnology have been observed and noted in recent years. One such trend is the trend in partnering and acquisition of deals. This is applicable to the business perspective towards the delivery and realization of more up to date by products. So basically there are a lot of sectors in which biotechnology can affect. But one of the most suitable choices is pharmaceutical sector. People are focusing more and more now days on the use of biotechnological products. There are a lot of independent biotechnology companies which deals directly with these biotechnological products. Biotechnology is used to develop commercial product also. Biotechnology becomes central priority of the government’s research policy to ensure a high standing of biosciences and to develop newer innovation techniques. At present there are 25 different initiatives to financially support universities, research institutes. They all are working like a chain having same common objectives. There is a healthy competition in between the companies which in turn increases the level of biotechnological products. The key element of this initiative is Biopharma competition. So it depends on the people how they utilize biotechnological products for their better interest.

Biotechnology is a technology which never goes opposite to the nature.

We have to improve the biotechnology with the help of nature. Now a days lots of course are based on Biotechnology in various colleges all over the world. It becomes popular to all the students also.

Source:
http://www.biotechblog.org/entry/top-trends-biotechnology/

Introduction

Genetic disorders are becoming common nowadays due to stressful modern lifestyle. Latest technologies are the added values to create many genetic disorders. To overcome the disorders, Gene therapy is a blessing. In order to compensate abnormal genes and make a good gene, genetic material is introduced into cells. In this way, mutated gene will act as a normal gene. Let us see in detail.

Ways to insert the gene

There are indirect ways need to be followed to make a gene to function as if it is inserted directly does not function. Carrier also called as vector is used to deliver the gene. In the place of vectors, virus play the role as they are getting modified and hence people are not affected with new diseases when it is integrated into the chromosome of the human cell.

The vectors need to get injected to specific tissue in the body or outwardly patient’s cell is removed and exposed to the vector. In either of the ways need to be again returned to the patient. Successful treatment makes proper genes and genetic disorders get solved.

Gene therapy for treating cancer

Cancer is the dangerous disease and there are many ways to cure cancer including surgery, chemotherapy, and radiation. But cancerous cells in due course again spread and hence it is a deadly disease. Gene therapy is the best way discovered nowadays for treating cancer.
Let us see the basic fundamentals of cells. cells include packets of data in genes, created either from DNA or RNA. Sequence is there for DNA and if it is in the order, there will be no problem. But at the same time If there is disorder occurs in portion of the genes either turning or changing the position, cells lost their control and abnormal growth is seen which result in cancerous tumors. It can spread in mouth, breast, lung etc.,

Specialists in Gene therapy analyze the patient’s criticality first and follow the treatment procedures. One way is they replace missing or mutated genes into wholesome genes. Inserting totally new genes for fighting cancer, placing DNA into cancerous cells to undergo chemotherapy and radiation or injecting bad gene to destroy them etc., Mesothelioma type of cancers are not at all responded in formal therapies and hence one need to undergo gene therapy essentially. Need to have consultations with doctors to overcome their deadly disease.

Gene therapy importance

Doctors decide whether gene therapy is suitable by the following approaches. If genetic disorders are from mutations in one or more genes or whether a normal copy of the gene that is available in the patient is enough to fix the problems in the affected cells, then doctors determine that gene therapy will be more helpful rather than going for traditional methods.

Conclusion

Genetic engineering is a vast topic. Latest Science innovations in the field of genetic engineering yields for gene therapy. Doctors and scientists together working to find out whether gene therapy is the best suitable way for treating deadly diseases like cancer and others. Let us salute for the positive force of gene therapy.

Source:
http://www.biotechblog.org/entry/biotechnology-gene-therapy/

Life Un(Ltd), Charis Thompson, Three Times a Woman- A Gendered Economy of Stem Cell Innovation Pt 1
This presentation was part of CSW #39;s Life (Un)Ltd project, and took place on October 24, 2012. Life (UnLtd) is an interdisciplinary project initiated by CSW Associate Director Rachel Lee that engages recent developments in biosciences and biotechnology, foregrounding critical, aesthetic, and ethics-based approaches to what have become global research and marketing industries.From:UCLAViews:19 0ratingsTime:36:53More inEducation

Originally posted here:
Life Un(Ltd), Charis Thompson, Three Times a Woman- A Gendered Economy of Stem Cell Innovation Pt 1 - Video

Life UnLtd, Charis Thompson, Three Times a Woman A Gendered Economy of Stem Cell Innovation Pt 2
This presentation was part of CSW #39;s Life (Un)Ltd project, and took place on October 24, 2012. Life (UnLtd) is an interdisciplinary project initiated by CSW Associate Director Rachel Lee that engages recent developments in biosciences and biotechnology, foregrounding critical, aesthetic, and ethics-based approaches to what have become global research and marketing industries.From:UCLAViews:16 0ratingsTime:27:24More inEducation

Read more:
Life UnLtd, Charis Thompson, Three Times a Woman A Gendered Economy of Stem Cell Innovation Pt 2 - Video

blood banks | Umbilical Cord Blood Banking Could Be an Investment in Our Future Health
http://www.cordbloodrecommendation.com Researchers are hopeful that within five years, pieces of the tissue can be used to repair damaged livers and within 15 years, actual liver transplants may be done using lab-grown livers made from cord blood. This is why all of the best companies use the same courier. What is flexing Blood saving?Flex blood caching is a breakthrough in blood caching. As a result, patients can recover faster, thus preventing kidney complications arising from tissue damage. It can be anywhere from about $1500 to about $1800. Following the treatment, David #39;s body created a new blood supply complete with white cells, hence a new immune system. "" Some clinical trials show that the regeneration of the damaged neurons can be done through transplantation of the stem cells in the cord blood. But these are just some diseases from amongst the 70 diseases that can be cured by stem cell, and the list keeps on getting longer. It further saves you from the trouble of locating a matching donor when transplants are concerned. ""Stem cells can be found in multiple locations within our body. -based weekly, that documents breakthrough papers in biotechnology. The umbilical cord is the cord that attaches from the babies belly button to the placenta in the mother #39;s womb during pregnancy. The amount of stem cells is very crucial for any treatment. Private banks on the other hand are for-profit organizations which store blood from the baby for the exclusive use of the donor or donorFrom:loshoteles enmedellinViews:0 0ratingsTime:01:01More inScience Technology

See the original post here:
blood banks | Umbilical Cord Blood Banking Could Be an Investment in Our Future Health - Video

The Biotech Age: The Business Of Biotech And How To Profit From It - Richard Oliver
ll4.me The Biotech Age: The Business Of Biotech And How To Profit From It - Richard Oliver A look at the forefront of an industry revolution ""I #39;ve been deep inside the biotech industry since its infancy. This book provides fresh insights about how it started, what drives it, and most importantly, where it #39;s going.""--Scott W. Morrison, partner, Ernst Young LL Richard W. Oliver predicted the onset of a new era with The Coming Biotech Age. Now that age is here--and companies are reaping the benefits of this incredible new revolution. As biotech companies become the new economic engines of growth and innovation, businesses must have access to the latest developments of this area of research. In a special revised edition, now titled The Biotech Age, Oliver has created the first practical guide to this fascinating realm of scientific development. With updated information on the latest research, examples of biotech breakthroughs, and a close examination of current biotech issues such as cloning and stem cell research, The Biotech Age presents an accessible overview of the business of biotechnology and its vast implications and opportunities for all types of industries. This is a topic no one can afford to miss--especially future-minded executives and investors in cutting-edge technologies.Words: and opportunities, companies it, how deep is, inside from, it must have, must have it, young ernstAuthor: Oliver, Richard Publisher: McGraw-Hill Illustration: N Language: ENG Title ...From:jonisims9854Views:0 0ratingsTime:00:10More inPeople Blogs

Link:
The Biotech Age: The Business Of Biotech And How To Profit From It - Richard Oliver - Video

SAN DIEGO, CA--(Marketwire - Nov 7, 2012) - COARE Biotechnology (COARE) and ChemDiv, Inc. (ChemDiv) announced today the formation of a strategic alliance that will offer a fully integrated gene-to-clinic services aimed at development of therapeutic agents that selectively affect cancer stem cells (CSC).

Under terms of this agreement, COARE contributes its pioneering research on the role of Doublecortin-like Kinase 1 (DCLK1) in proliferation and differentiation of CSC including relevant screening reagents and know-how. ChemDiv provides chemistry and biology expertise, including i) small molecule screening libraries, Medicinal Chemistry support, ii) assay adaptation, development and implementation, iii) in vivo testing and iv) advanced preclinical services including DMPK/tox. Dr. Ilya Okun, VP of Biology and CTO at ChemDiv, said: "COARE scientists, have identified a novel enzyme, DCLK1, which plays a key role in development of many solid tumors. This kinase is a promising and tractable target for the discovery of novel specific anti-cancer therapies. I am very excited that the collaboration between ChemDiv and COARE on this program will allow for discovery of new ways to treat a panel of cancers, for which there currently is no effective medicine."

Dr. Courtney W. Houchen, Chief Medical Adviser and cofounder, said, "We are excited at this partnership opportunity and the fact that this collaboration with ChemDiv will bring to the doorstep of both pharmaceutical and biotechnology companies worldwide, our research, expertise and our proprietary assays to help discover small molecules that target, and potentially eradicates or functionally inactivates the most resistant subpopulation of most tumors, the cancer stem cells."

About ChemDiv ChemDiv, Inc. is a Fully Integrated Target-to-Clinic Contract Research Organization (CRO) headquartered in San Diego, CA USA. The company features multiple research and development (R&D) subsidiaries in Russia, Ukraine and China as well as business and logistics operations around the world. We engage pharmaceutical and biotech partners by offering 'one stop' drug discovery and development services based on a project-, FTE- and risk sharing collaborative modes. More information about ChemDiv is available at http://www.chemdiv.com.

About COARE COARE Biotechnology is a research driven biotechnology company dedicated to developing novel anti-cancer therapeutic agents designed to treat solid tumor cancers headquartered in Oklahoma City, OK USA. Our agents are directed against DCLK1, a novel molecular target whose mechanism of action involves multi-pathway, multi-functional cancer inhibition. Recently completed research has shown that this stem cell related protein plays a functional role and is increased in human pancreatic cancer. This protein works to turn off natural tumor suppressors and turns on cancer-causing genes. We are determined to eradicate solid tumor cancers in our lifetime. For additional information about us go to http://www.coarebiotechnology.com

Continued here:
Coare Biotechnology and ChemDiv Establish Co-Marketing and Service Collaboration

26. Medical Biotechnology: Part Ic. Animal and Human Cloning and Genetic Engineering NQ
Some of the same techniques described for stem cell research, have been extended and applied to animal cloning, creating part of the controversies surrounding both topics. What is cloning? Cloning an organism (as a totally different process distinguished from cloning a gene) is a process whereby all members are directly descended, asexually, from a single organism by......various ways, as we show in this section, and this demonstrates that all the information required for an organism and its development are in the a single cell. many animals have now been cloned, including, sheep (Dolly), cattle, pigs, mice, rats, fish, dogs, cats, horses, mules, and more recently monkeys. Can humans be cloned? Probably.From:Albert KauschViews:0 0ratingsTime:25:37More inScience Technology

Link:
26. Medical Biotechnology: Part Ic. Animal and Human Cloning and Genetic Engineering NQ - Video

NEW YORK, Oct. 30, 2012 /PRNewswire/ -- As many scientists and researchers are aware, biology entails an incredibly complex series of mechanisms and processes that still amaze intelligent minds today. While these biological systems have shaped the world, the application of modern biotechnology has only existed for approximately for three decades. According to a recent FundWeb article, this year marks the 30th anniversary of the "first biotechnology drug approved for human medical use," known as Humulin, "a genetically engineered version of natural human insulin for the treatment of diabetes." Since 1982, biotechnology has seeped its way into modern science and popular applications, which has led many to believe that biotechnology is the next "technology super-cycle." David Lichtenstein, biotechnology supporter and BrainStorm Cell Therapeutics investor, agrees that the science certainly holds the potential to change culture and the way humans live and solve problems.

David Lichtenstein states, "It is amazing to look back at the last 30 years a small period in terms of scientific development and realize just how far biotechnology has come. I expect these applications to become more present in our society, improving every facet of daily life." According to the article, such varied use of biotechnology has been witnessed since the original introduction of Humulin. It states, "Roughly two-thirds of all new drugs approved by the FDA have been discovered and/or developed by a biotechnology company at some stage." In addition to medical use, biotechnology has encouraged significant changes in agriculture and industrial manufacturing."

According to the article, financial analysts believe that biotechnology holds the potential for creating the next major socio-economic era in modern culture. It explains that such possibility for growth opens up a wide variety of investment opportunities in biotechnology. However, few have committed to investing in the science. Having already made significant investments in the field of biotechnology, David Lichtenstein knows that the industry holds promise. At BrainStorm Cell Therapeutics alone, there are projects that focus on repairing ALS, Multiple Sclerosis and Parkinson's disease through stem cell therapy.

David Lichtenstein concludes, "As far as investment strategies go, biotechnology is one field that is new, exciting and offers opportunity for long-term profit. After close examination, I believe wary investors may change their mind about investing in this incredible field of science."

ABOUT:

David Lichtenstein is a supporter of the growth of biotechnology and has become a major investor in the innovative science. He is currently an investor in BrainStorm Cell Therapeutics, a biotechnology company that develops adult stem cell therapies to resolve medical issues associated with severe neurodegenerative disorders including ALS, Multiple Sclerosis and Parkinson's disease. In addition, David Lichtenstein has proven his worth as an investment strategist, having steadily built the Lightstone Group since 1988. As chairman and CEO of the Lightstone Group, David Lichtenstein has carefully developed a diverse portfolio of properties allowing the company to become of the most widespread and successful privately held real estate companies in the United States of America.

View post:
David Lichtenstein: Biotechnology is Rich Area for Investment

NEW YORK, NY--(Marketwire - Oct 15, 2012) - The Biotechnology Industry has seen increased investor interest in 2012 as it continues to impress with strong gains. The iShares NASDAQ Biotechnology Index ETF (IBB) has gained over 35 percent this year, more than double the S&P 500 Index's gain of 15 percent. New legislation, increased mergers & acquisition activity as a result of major patent expirations have all been contributing factors to the industry's rapid rise in 2012. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Amicus Therapeutics, Inc. ( NASDAQ : FOLD ) and Osiris Therapeutics, Inc. ( NASDAQ : OSIR ).

Access to the full company reports can be found at: http://www.FiveStarEquities.com/FOLD http://www.FiveStarEquities.com/OSIR

The Biotechnology Industry Organization (BIO) has recently praised the introduction of the High Technology Small Business Research Incentives Act. The new legislation would allow investors of joint venture R&D projects to utilize the losses and tax credits.

"Through the tax code, Congress historically has provided opportunities that encourage private investment in pre-revenue, R&D-intensive companies. The early growth of the biotech industry in the 1980s was due in part to the ability of investors to support projects aimed at finding new cures and treatments through similar joint ventures. This legislation will help spur greater private investment in biotech and other R&D intensive industries," BIO's President and CEO Jim Greenwood said in a statement.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Amicus Therapeutics is a biopharmaceutical company at the forefront of developing therapies for rare diseases. Shares of the company soared last Thursday after it reported positive preliminary results from an ongoing Phase 2 study for the treatment of people with Pompe disease.

Osiris Therapeutics, having developed the world's first approved stem cell drug Prochymal, is the leading stem cell company. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets. The company recently reported that Swissmedic has invoked rapid authorization procedures for the Prochymal review.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

Read the rest here:
Biotech Industry Look to Benefit From New Act Designed to Promote R&D Joint Ventures

NEW YORK, NY--(Marketwire - Oct 1, 2012) - The Biotechnology Industry has seen increased investor interest in 2012 as it continues to impress with strong gains. The iShares NASDAQ Biotechnology Index ETF (IBB) has gained over 35 percent this year, more than double the S&P 500 Index's gain of 15 percent. New legislation, increased mergers & acquisition activity as a result of major patent expirations have all been contributing factors to industry's rapid rise in 2012. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on StemCells, Inc. ( NASDAQ : STEM ) and Neuralstem, Inc. ( NYSE : CUR ).

Access to the full company reports can be found at: http://www.FiveStarEquities.com/STEM http://www.FiveStarEquities.com/CUR

The Biotechnology Industry Organization (BIO) has recently praised the introduction of the High Technology Small Business Research Incentives Act. The new legislation would allow investors of joint venture R&D projects to utilize the losses and tax credits.

"Through the tax code, Congress historically has provided opportunities that encourage private investment in pre-revenue, R&D-intensive companies. The early growth of the biotech industry in the 1980s was due in part to the ability of investors to support projects aimed at finding new cures and treatments through similar joint ventures. This legislation will help spur greater private investment in biotech and other R&D intensive industries." BIO's President and CEO Jim Greenwood said in a statement.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

StemCells is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. Shares of the company surged last Thursday after it reported it has enrolled its first patient in a Phase I/II clinical trial for the treatment of a chronic spinal cord injury.

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. The company recently reported it has been approved to commence an ischemic stroke trial in China.

Five Star Equities provides Market Research focused on equities hat offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

View original post here:
Biotech Industry Applauds Introduction of the High Technology Small Business Research Incentives Act

SAN DIEGO--(BUSINESS WIRE)--

Medistem Inc (Pink Sheets:MEDS) announced today the initiation of a collaboration with Superview Biotechnology Co. Ltd, a subsidiary of Yinhuan Holding Co from Yixing, China. The joint work will be aimed at using proprietary stem cell lines developed by Medistem for screening of monoclonal antibodies for therapeutic activity in the area of regenerative medicine. As part of the collaboration, the two companies will evaluate various candidates jointly, as well as apply for grants and share research data.

To date, the majority of stem cell companies are focusing on the stem cell itself being a product. By collaborating with Superview Biotechnology, we aim to assess the feasibility of developing antibodies that can modulate the activity of stem cells that already exist in the body, said Thomas Ichim, CEO of Medistem. This approach not only provides methods of activating stem cells but also allows for the development of stem cell adjuvant therapies that could be used to resurrect stem cell candidates that failed in clinical trials.

Superview Biotechnology has developed proprietary methods of rapidly generating monoclonal antibodies to esoteric protein targets. Medistem has a history of success in the area of stem cells, being the only company to take a stem cell product from discovery to FDA clearance in the short span of 4 years.

One of the significant driving forces behind our company is to develop innovative targets for our monoclonal antibodies. Although monoclonal antibodies have generated sales of billions of dollars in areas ranging from rheumatoid arthritis, to cancer, to preventing blindness, we feel that the potential of this therapeutic tool is only beginning to be recognized, said Jiong Wu, CEO of Superview Biotechnology. Our opinion is that the barriers to entry for monoclonal antibody-based therapies modulating endogenous stem cells is lower than stem cell based therapies. We are eager to work with the Medistem team at exploring this hypothesis.

A joint grant is expected to be filed with the National Natural Science Foundation of China to support part of the proposed collaboration by end of October, 2012.

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Read more:
Medistem and Superview Biotechnology Co. Ltd. Initiate Collaboration on Therapeutics Development Using Antibody and ...

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announces Therapeutic Workshops on Cancer stem cell therapy, kinase drugs, and ultra rare diseases planned for the upcoming BIO Investor Forum. Hosted by BIO, the 11th annual event will take place at the Palace Hotel on October 9-10 in San Francisco, Calif.

This years Therapeutic Workshops will address some of the most exciting therapeutic advances for the biotech industry. We have worked very closely with this years esteemed Advisory Committee to identify topics that will engage investors and industry alike, said Alan Eisenberg, executive vice president, Emerging Companies & Business Developmentat BIO.

Therapeutic Workshops will feature senior-level industry executives, scientific officers and leading clinical experts that represent innovative investment opportunities in the biotech industry.

Therapeutic Workshops include:

The BIO Investor Forum features public and venture-stage company presentations, expert-led, business roundtables, one-on-one investor meetings and networking opportunities.

To learn more about the BIO Investor Forum, including registration and program information, please visit here. Advance media registration is available here. Registration is complimentary for credentialed members of the media and qualified investors.

BIO is pleased to recognize the leadership provided by the BIO Investor Forum Conference sponsors including Supporting Bank Stifel, Nicolaus & Company. BIO Double Helix and Helix Sponsors include Abbott Biotech Ventures, Amgen Ventures, Baxter Ventures, J&J Development Corporation, MedImmune Ventures, GlaxoSmithKline, Merck and Pfizer.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtechNOW.

Visit link:
BIO Announces Therapeutic Workshops for 11th Annual BIO Investor Forum

SAN DIEGO--(BUSINESS WIRE)--

This week in the journal Scientific Reports (Nature Publishing Group), scientists from Allele Biotechnology describe an important advance in the generation of stem cells capable of producing all the different tissues of the human body. In an article entitled Feeder-Free Derivation of Human Induced Pluripotent Stem Cells with Messenger RNA, Alleles scientists present the fastest and safest method yet for converting ordinary human skin cells into induced pluripotent stem cells (iPSCs).

The scientific efforts were led by Dr. Luigi Warren, whose pioneering work on footprint-free reprogramming using messenger RNA was the foundation for Alleles breakthrough. Through the united efforts of Dr. Warren and the scientists at Allele Biotechnology, his technique was re-engineered to increase cell conversion efficiency and eliminate any use of potentially unsafe reagents, while substantially reducing the time and effort needed to make stem cells. Dr. Warren believes that because of its advantages this technology should become the method of choice for iPSC cell banking.

According to Dr. Jiwu Wang, corresponding author on the paper and CEO of Allele Biotechnology, This advance in stem cell derivation will enable both fundamental scientific research and clinical applications which has been the mission of Allele Biotechnology from its inception.

Allele Biotechnology and Pharmaceuticals Inc. is a San Diego-based biotechnology company that was established in 1999 by Dr. Jiwu Wang and colleagues. A research based company specializing in the fields of RNAi, stem cells, viral expression, camelid antibodies and fluorescent proteins; Allele Biotechnology has always striven to offer products and services at the cutting edge of research.

Continue reading here:
Allele Biotechnology Announces New Advance in Production of Human Stem Cells

NEW YORK, NY--(Marketwire -07/24/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 38 percent and 37 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on StemCells, Inc. (STEM) and Keryx Biopharmaceuticals (KERX).

Access to the full company reports can be found at:

http://www.ParagonReport.com/STEM http://www.ParagonReport.com/KERX

Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

StemCells is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The company recently announced preclinical data demonstrating that its proprietary human neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer's disease. Shares of the company have soared nearly 90 percent this year.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Shares of the company have rebounded nearly 50 percent over the last three months.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer

Continue reading here:
StemCells and Keryx Biopharmaceuticals Showing Strong Gains as Biotechnology Industry Soars in 2012

CEDAR KNOLLS, NJ--(Marketwire -06/27/12)- MYOS Corporation (MYOS), a company focused on the discovery, development and commercialization of muscle health and performance therapeutic products, today announced that it has appointed Sol J. Barer, Ph.D., to Chair its Scientific Advisory Board.

Dr. Barer is the former Chairman and Chief Executive Officer of Celgene Corporation, a leading global biotechnology company specializing in cancer, hematologic and immunologic pharmaceuticals. He retired last year from a successful Celgene career where he served as Chairman from 2006 to 2011, and Chief Executive Officer from 2006 to 2010. Prior, he served as Celgene President and Chief Operating Officer since 1993, and 1994, respectively.

Dr. Barer serves as a director of a number of corporate and not-for-profit Boards.

Commenting on his appointment to Chairman of the MYOS Scientific Advisory Board, Dr. Barer said, "The nascent field of muscle biology and the technologies which maximize the health and performance of this organ system represents significant, previously untapped potential. MYOS is positioning itself to play an important and meaningful role in the discovery, development and clinical use of new products which will improve the health and performance of an organ system which we often forget is so vital to the quality of our lives.

"I am especially pleased to serve in this position so early in the Company's development, and to collaborate with its Board and growing management team," he added.

Commenting on Dr. Barer's appointment, Chairman of the MYOS Board of Directors Robert J. Hariri, M.D., Ph.D., said, "It is a special honor to welcome my long time colleague, friend and mentor, Dr. Barer to the Advisory Board. I consider Sol to be one of the visionary leaders who have helped shape the biotechnology industry, and truly value his insight into our sector's science, marketplace and corporate development."

Dr. Hariri serves as chief executive officer of Celgene Cellular Therapeutics, a division of Celgene Corporation, a position he has held since 2005. Prior to joining Celgene Cellular Therapeutics as president in 2002, Dr. Hariri was founder, chairman and chief scientific officer at Anthrogenesis Corporation/LIFEBANK, Inc., a privately held biomedical technology and service corporation involved in human stem cell therapeutics, which was acquired by Celgene in 2002.

About MYOS CorporationMYOS Corporation is a development stage company focused on the discovery, development and commercialization of therapeutic products that improve muscle health and performance (www.myoscorp.com).

MYOS is the owner of MYO-T12, the world's first clinically demonstrated myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. MYO-T12 is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards of physical health and wellness enhancement. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company," visit http://www.MYOT12.com.

Forward-Looking StatementsAny statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful launch of Myo-X, the ability to generate the forecasted revenue stream and cash flow from sales of Myo-X, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

Visit link:
MYOS Names Veteran Biotechnology Executive Dr. Sol J. Barer to Chair Scientific Advisory Board

TAIPEI, June 25, 2012 /PRNewswire-Asia/ -- TaiGen Biotechnology Company, Limited ("TaiGen") and Zhejiang Medicine Company, Limited ("ZMC") today announced that they have signed an exclusive agreement to manufacture and commercialize nemonoxacin, a novel broad-spectrum antibiotic, in China (excluding Hong Kong, and Macau). Nemonoxacin is a novel broad-spectrum non-fluorinated quinolone antibiotic under development for respiratory infections. TaiGen will be responsible for completing the Phase 3 clinical trial for community acquired pneumonia ("CAP") in China. ZMC will be responsible for manufacturing, sales and marketing of nemonoxacin in China through its wholly-owned subsidiary, XinChang Pharmaceuticals. TaiGen will retain full development and commercialization rights outside the licensed territory including Taiwan, the United States, European Union, and Japan. Under the terms of the agreement, TaiGen will receive an upfront payment of US$ 8 million from ZMC and will receive additional milestones as well as royalties on product sales. The term of the agreement is 20 years.

Nemonoxacin has demonstrated efficacy and safety in CAP and diabetic foot infection in multinational and multi-center clinical trials conducted by TaiGen. In particular, nemonoxacin has excellent activity against drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and quinolone-resistant MRSA. Nemonoxacin is taken once-a-day and available in both oral and intravenous formulations. Currently, TaiGen is completing a Phase 3 CAP trial with more than 500 patients from Taiwan and mainland China and expects to file new drug applications in Taiwan and mainland China simultaneously in early 2013.

China is one of the major antibiotic markets in the world. According to IMS, the sales of antibiotics in 2011 were approximately US$ 11 billion (RMB 68 billion) and account for almost 20% of the total pharmaceuticals sales. Rate of antibiotic resistant infections in China is among the highest in the world.

Mr. Li Chun Bo, Chairman of the ZMC, commented, "We are impressed with nemonoxacin's broad spectrum activity towards drug-resistant bacteria, in particular, MRSA, and excellent safety profile. We are excited to establish this partnership with TaiGen because of its reputation as a premier research-based biotech company in Asia. This partnership will break new ground for cross-strait collaboration in the pharmaceutical industry. Nemonoxacin will be a major addition to ZMC's antibiotic product line and significant profit driver".

Dr. Ming-Chu Hsu, President and Chief Executive Officer of TaiGen, said, "China is the world's fastest growing pharmaceutical market. It is poised to overtake Japan as the second largest pharmaceutical market. We are extremely please to establish our nemonoxacin partnership with ZMC, a first-class pharmaceutical company and major player in the Chinese antibiotics market. With nemonoxacin, TaiGen and ZMC together will bring new medicine to treat unmet medical needs in China. This partnership will not only set a new record for pharmaceutical licensing involving a Taiwanese and a mainland Chinese company but hopefully will also become a model of the future collaborations," Dr. Hsu also added, "With the conclusion of the partnership in China, we will actively pursue nemonoxacin licensing discussions in other territories such as European Union."

About Zhejiang Medicine

Zhejiang Medicine Company, Limited is a leading pharmaceutical company in China specializing in sales and distribution of pharmaceuticals and manufacturing of active pharmaceutical ingredients (vitamins and antibiotics). Its sales revenue in 2011 is US $740 million (RMB 4.8 billion). ZMC is a leader in the Chinese antibiotic market with levofloxacin, vancomycin, and teicoplanin in the product line. ZMC's Lai Li Xin, a branded levofloxacin, is one of the top selling antibiotics in China with 2011 sales exceeding US $110 million (RMB 735 million). In addition to pharmaceuticals sales, ZMC is also known for its manufacturing quality. Its vancomycin active pharmaceutical ingredient has obtained GMP qualification from US Food and Drug Administration (FDA) and exported to western countries. ZMC is publicly listed in the Shanghai Stock Exchange (600216) and has a market capitalization of RMB 11 billion.

About TaiGen Biotechnology

TaiGen Biotechnology is a leading research-based and product-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, mainland China. TaiGen has full discovery research capacity in Taiwan and clinical development in mainland China/Taiwan/US. In addition to nemonoxacin, TaiGen has two other in-house discovered new chemical entities in clinical development under IND with US FDA: TG-0054, a chemokine receptor antagonist for stem cell transplantation and chemosensitization, in Phase 2 and TG-2349, a HCV protease inhibitor for treatment of chronic hepatitis infection, in Phase 1. Both TG-0054 and TG-2349 are currently in clinical development in the US.

Disclaimer

See the original post:
TaiGen Biotechnology Out-Licensed China Rights of Novel Antibiotic, Nemonoxacin, to Zhejiang Medicine

SHENZHEN, China, May 29, 2012 /PRNewswire-Asia/ --Beike Biotechnology Co., Ltd ("Beike") announced that it has been awarded AABB accreditation for cord blood and cord tissue banking. This accreditation has been granted following an intensive on-site assessment by AABB assessors and establishes that the level of medical, technical and administrative performance within the facility is in accordance with the AABB standards or exceeds those set by AABB. With this achievement, Beike becomes China's first and only AABB-accredited stem cell bank for both cord blood and cord tissue banking.

Ying Song, MD, PhD, Medical Director of Beike, stated, "It is a proud moment for us that Beike is the first and the only stem cell bank in China to possess AABB accreditation for both cord blood and cord tissue and this reflects our commitment to quality. It is also noteworthy to mention that Beike is among the first stem cell banks in the world to receive AABB accreditation for cord tissue banking which positions Beike as a leader in stem cell preservation."

Beike began the comprehensive AABB accreditation process in March 2010 and completed the on-site assessment in September 2011. The accreditation assessment included stem cell processing, records, document control, inspection and testing, technician training, sample identification, traceability and validations. During this audit, it was determined that Beike's medical, technical and administrative performance met the standards set by the AABB. Beike was issued its AABB certificate in January 2012.

Dr. Shengqin Ye, President of Beike, commented, "We are extremely pleased to have been granted this accreditation. With this, Beike has once again demonstrated a commitment to advanced learning, continuous improvement and innovation to sustain the highest possible level of quality and safety."

To meet AABB standards, Beike adopted new technology for stem cell processing (AXP AutoXpress system), storage (BioArchive Systems), and testing (Beckman hematology analyzer LH750 and Tecan Freedom EVOlyzer). Additionally, the company optimized its information technology platform and software systems, adding an advanced bar code management system, real-time monitoring capabilities, and an advanced enterprise resource planning (ERP) system to its call center.

About Beike Biotechnology Company:

Shenzhen Beike Biotechnology Co., Ltd. is China's leading biotechnology company focusing on banking adult stem cells and developing new cell based medicinal products. Headquartered in Shenzhen (near Hong Kong) with a flagship regenerative medicine facility at the China Medical City in Jiangsu province, Beike produces a full line of stem cell products derived from umbilical cord, cord blood and autologous bone marrow.

About AABB:

AABB (formerly the American Association of Blood Banks) is an international non-profit body dedicated to developing the highest standards in blood and cord blood banking, transfusion medicine and cellular therapy. The association is committed to improving health by developing and delivering standards, accreditation and educational programs that focus on optimizing patient and donor care and safety.

Based in the United States, AABB represents more than 2,000 institutions and 8,000 individuals in 80 countries, involved in collecting, processing, testing, distributing, or transfusing blood, blood components, or cellular therapy products.

Read more from the original source:
Beike Earns AABB Accreditation for Cord Blood and Cord Tissue Banking

16 May 2012

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Angel signs new contract with ReNeuron to provide GMP (KOSDAQ: 018290.KQ - news) cell manufacturing services for completion of stroke clinical trial

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, has signed a new contract with ReNeuron Group (Berlin: RQE.BE - news) plc (AIM:RENE) to perform GMP manufacturing services in support of the final part of the PISCES Phase 1 clinical trial of its ReN001 stem cell therapy for stroke; the value of the contract was not disclosed.

Dr Stewart White, Acting CEO, Angel Biotechnology (Berlin: A3G.BE - news) said: "Angel is very proud to be providing ReNeuron with additional manufacturing support to complete this ground breaking Phase 1 clinical trial. This contract is further recognition of the strong partnership between Angel and ReNeuron, and also reaffirms both companies commitment to provide solutions for a real clinical need."

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Acting CEO/Commercial Director http://www.angelbio.com

See original here:
Angel Biotechnology - Angel signs new contract with ReNeuron

NEW YORK, NY--(Marketwire -03/28/12)- Biotechnology stocks have been on an impressive run this year as favorable legislation out of Washington is allowing biotech companies of all sizes to more easily navigate regulations. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Advanced Cell Technology Inc. (OTC.BB: ACTC.OB - News) and PharmAthene Inc. (AMEX: PIP - News). Access to the full company reports can be found at:

http://www.fivestarequities.com/ACTC http://www.fivestarequities.com/PIP

The Biotechnology Industry Organization (BIO) recently applauded the House Energy and Commerce Committee's passage of the Medicare Decisions Accountability Act, H.R. 452, which would repeal the Independent Payment Advisory Board (IPAB) established in the health care reform law. BIO also issued a press release applauding the Senate on the passage of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act. The JOBS Act creates an "on-ramp" to the public market for emerging growth companies, allowing them five years to focus on conducting critical research that can lead to cures for debilitating diseases before having to divert funds to costly regulations, BIO reports.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.

Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. Earlier this month the company filed with the Securities and Exchange Commission a proxy statement containing a shareholder proposal for a reverse split of its common stock. "This reverse stock split, which should better align the company's capital structure with its stage of development, and an accompanying Nasdaq listing application, will represent a significant step toward creating long-term shareholder value and building ACT into a world-class player in the regenerative medicine space," said Gary Rabin, chairman and CEO of ACT.

PharmAthene, Inc., a biodefense company, engages in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States. For the year ended December 31, 2011, PharmAthene recognized revenue of $24.3 million, compared to $21.0 million in 2010.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.fivestarequities.com/disclaimer

Read this article:
Advanced Cell Technology and PharmAthene Poised to Benefit From Positive Legislation